Fangzhou Inc., a leading provider of AI-driven Internet healthcare solutions, has been named an “Outstanding Strategic Health Ecosystem Partner” by Novo Nordisk at the 2025 Health Ecosystem Partner Alliance Summit during the 8th China International Import Expo (CIIE) in Shanghai. The announcement highlights a deepening collaboration between the two companies to advance digital innovation in chronic disease management, particularly in diabetes and weight management. Novo Nordisk expanded its Health Ecosystem Alliance, initially launched in 2023, to foster joint development and synergies among partners. Fangzhou’s recognition underscores its pivotal role in integrating artificial intelligence into healthcare delivery and its contributions to transforming chronic disease care. The partnership, formalized in July 2025, aims to align service offerings with patient needs by co-developing digital chronic disease management models. These models are designed to empower healthcare providers, patients, and stakeholders through data-driven, personalized care solutions. Fangzhou has pioneered the industry’s first intelligent “AI + Weight Management” solution, leveraging its proprietary XJ and XS Large Language Models as the foundation of its AI infrastructure. The company was selected as a key participant in the national “Healthy China: AI + Weight Management Initiative,” developed in collaboration with the China Food and Drug Institutions Quality and Safety Promotion Association. This initiative promotes standardization, technological advancement, and evidence-based practices in digital weight management. In diabetes care, Fangzhou has gained strong recognition from Novo Nordisk for its expertise in AI-powered healthcare services and medication management. Together, the companies are driving a strategic shift from reactive disease treatment to proactive health management, combining Fangzhou’s digital infrastructure with Novo Nordisk’s innovative therapies for diabetes and obesity. Dr. Xie Fangmin, Founder, Chairman, and CEO of Fangzhou, emphasized the significance of the collaboration: “As a key partner of Novo Nordisk’s Health Ecosystem Alliance, Fangzhou will continue to leverage our XJ and XS Large Language Models to deepen technological innovation and deliver accessible, efficient, end-to-end chronic disease management services to a broader population.” Through its expanding AI + Chronic Disease Management ecosystem, Fangzhou is advancing the industry’s transition from traditional care models to systematic, evidence-based approaches. The company remains committed to an open, collaborative strategy with industry leaders to enhance the quality and efficiency of digital healthcare, supporting the broader goals of Healthy China 2030. Novo Nordisk, a global healthcare leader founded in 1923 and headquartered in Denmark, continues to drive innovation in combating serious chronic diseases, particularly diabetes, through scientific breakthroughs, expanded access to medicines, and disease prevention. Fangzhou Inc. (HKEX: 06086) serves over 52.8 million registered users and connects with 229,000 physicians as of June 30, 2025. The company specializes in AI-enabled precision medicine and tailored medical care, positioning itself at the forefront of digital health transformation in China. For media inquiries or interviews, contact Xingwei Zhao, Associate Director of Public Relations, at [email protected]. This press release contains forward-looking statements that may not materialize due to various risks and uncertainties. Readers are advised not to place undue reliance on these statements.